platinum has been researched along with Adenocarcinoma, Clear Cell in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, J; Gao, QL; Huo, Y; Jiang, J; Jiao, X; Li, G; Li, M; Li, R; Liu, J; Liu, X; Ma, G; Peng, Z; Song, C; Yu, Y; Zeng, S; Zhang, W; Zhao, Y | 1 |
| Gao, Y | 1 |
| Fujiwara, S | 1 |
| Chen, W; Shan, B; Wu, X; Yang, H; Ye, S; Zhong, S; Zhou, S | 1 |
| Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T | 1 |
| Angioli, R; De Felice, F; Giorgini, M; Iadarola, R; Lecce, F; Marchetti, C; Monti, M; Musella, A; Muzii, L; Palaia, I; Panici, PB; Perniola, G; Vertechy, L | 1 |
| Achatz, MI; Baiocchi, G; da Costa, AA; Guimarães, AP; Mantoan, H; Saito, A; Sanches, S; Valadares, CV | 1 |
| Abiko, K; Baba, T; Chikuma, S; Hamanishi, J; Honjo, T; Hosoe, Y; Ikeda, T; Kanai, M; Kawaguchi, A; Konishi, I; Mandai, M; Matsumoto, S; Matsumura, N; Minami, M; Mori, Y; Morita, S; Murayama, T; Shimizu, A; Ueda, A; Yamaguchi, K; Yokode, M | 1 |
| Cianci, S; Costantini, B; De Iaco, P; Fagotti, A; Perrone, M; Petrillo, M; Ronsini, C; Scambia, G | 1 |
| Cohen, JG; Diaz Moore, ES; Erickson, BK; Gunderson, CC; Holzapfel, M; Leath, CA; Leitao, MM; Moore, KN; Mueller, JJ; Prendergast, EN; Walsh, CS | 1 |
| Boren, TP; Miller, DS | 1 |
| Hedne, CN; Krishnaswamy, J; Kuthubutheen, J; Rajan, GP | 1 |
| Agarwal, R; Blagden, S; Diamantis, N; Gabra, H; Shaboodien, R | 1 |
| Bamias, A; Diakomanolis, E; Dimopoulos, AM; Markaki, S; Michalas, S; Milingos, S; Papadimitriou, C; Protopapas, A | 1 |
| Angioli, R; Basile, S; Bellati, F; Benedetti Panici, P; De Vivo, A; Manci, N; Muzii, L; Perniola, G | 1 |
| Isonishi, S; Saitou, M; Tanaka, T; Yasuda, M | 1 |
4 trial(s) available for platinum and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.
Topics: Adenocarcinoma, Clear Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Quality of Life; Tumor Microenvironment | 2022 |
Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Programmed Cell Death 1 Receptor; Salvage Therapy; Survival Rate | 2015 |
A case series of paediatric hearing preservation cochlear implantation: a new treatment modality for children with drug-induced or congenital partial deafness.
Topics: Acoustic Stimulation; Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Agents; Cerebellar Neoplasms; Child; Child, Preschool; Cochlear Implantation; Cochlear Implants; Deafness; Female; Follow-Up Studies; Goiter, Nodular; Hearing; Hearing Loss, Sensorineural; Humans; Infant; Kidney Neoplasms; Male; Platinum; Prospective Studies | 2012 |
12 other study(ies) available for platinum and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study.
Topics: Adenocarcinoma, Clear Cell; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies | 2023 |
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Quality of Life | 2023 |
Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Female; Fibrin Fibrinogen Degradation Products; Humans; Leukocyte Count; Lymphocyte Count; Middle Aged; Monocytes; Neoplasm Staging; Ovarian Neoplasms; Platelet Count; Platinum; Preoperative Period; Prognosis; Retrospective Studies; Serum Albumin; Survival Analysis; Treatment Outcome | 2020 |
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence | 2014 |
Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2015 |
Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies | 2017 |
Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Taxoids | 2010 |
Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Patient Selection; Platinum; Prognosis; Survival Rate | 2013 |
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cathepsin D; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Survival Analysis; Tumor Suppressor Protein p53 | 2004 |
Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Observation; Ovarian Neoplasms; Platinum; Prognosis; Prospective Studies | 2007 |
Mitochondria in platinum resistant cells.
Topics: Adenocarcinoma, Clear Cell; Apoptosis; Cystadenocarcinoma, Serous; Cytochrome c Group; Drug Resistance, Neoplasm; Female; Humans; Membrane Potentials; Mitochondria; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2001 |